Gastro-entero-pancreatic neuroendocrine tumors: Is now time for a new approach?

World J Clin Oncol. 2016 Apr 10;7(2):131-4. doi: 10.5306/wjco.v7.i2.131.

Abstract

Gastro-entero-pancreatic tumors (GEP-NETs) are rare neoplasms often characterized by an overexpression of somatostatin receptors. Thus, radiolabeled somatostatin analogues have showed an increasing relevance both in diagnosis and treatment, especially in low- and intermediate-differentiated GEP-NETs. These evidences have led to a growing development of new functional imaging techniques as 68Ga-DOTATATE positron emission tomography/computed tomography (PET/CT) proved useful in the management of these neoplasms. However these tumors have a heterogeneous behavior also modifying their aggressiveness through time. Therefore sometimes 18F-fluorodeoxyglucose PET/CT appears to be more appropriate to obtain a better assessment of the disease. According to these considerations, the combination of different functional imaging techniques should be considered in the management of GEP-NETs patients allowing clinicians to choose the tailored therapeutic approach among available options.

Keywords: 18F-fluorodeoxyglucose positron emission tomography/computed tomography; 68Ga-DOTATATE positron emission tomography/computed tomography; Diagnosis; Gastro-entero-pancreatic neuroendocrine tumor; Imaging.